Literature DB >> 21804762

Coverage of Megaprosthesis with Human Acellular Dermal Matrix after Ewing's Sarcoma Resection: A Case Report.

Robert M Whitfield1, Jeremy Rinard, David King.   

Abstract

A 23-year-old female with Ewing's Sarcoma underwent tibial resection and skeletal reconstruction using proximal tibial allograft prosthetic reconstruction with distal femur endoprosthetic reconstruction and rotating hinge. Human acellular dermal matrix, (Alloderm, LifeCell, Branchburg, NJ, USA), was used to wrap the skeletal reconstruction. Soft tissue reconstruction was completed with a rotational gastrocnemius muscle flap and skin graft. Despite prolonged immobilization, the patient quickly regained full range of motion of her skeletal reconstruction. Synthetic mesh, tapes and tubes are used to perform capsule reconstruction of megaprosthesis. This paper describes the role of human acellular dermal matrix in capsule reconstruction around a megaprosthesis.

Entities:  

Year:  2011        PMID: 21804762      PMCID: PMC3143457          DOI: 10.1155/2011/978617

Source DB:  PubMed          Journal:  Sarcoma        ISSN: 1357-714X


  10 in total

1.  Experimental assessment of the revascularization of acellular human dermis for soft-tissue augmentation.

Authors:  B L Eppley
Journal:  Plast Reconstr Surg       Date:  2001-03       Impact factor: 4.730

2.  Soft tissue reconstruction of megaprostheses using a trevira tube.

Authors:  G Gosheger; A Hillmann; N Lindner; R Rödl; C Hoffmann; H Bürger; W Winkelmann
Journal:  Clin Orthop Relat Res       Date:  2001-12       Impact factor: 4.176

3.  An 8-year experience of direct-to-implant immediate breast reconstruction using human acellular dermal matrix (AlloDerm).

Authors:  C Andrew Salzberg; Andrew Y Ashikari; R Michael Koch; Elizabeth Chabner-Thompson
Journal:  Plast Reconstr Surg       Date:  2011-02       Impact factor: 4.730

4.  Abdominal ventral hernia repair with current biological prostheses: an experimental large animal model.

Authors:  Matthew G Stanwix; Arthur J Nam; Helen G Hui-Chou; Jonathan P Ferrari; Harold M Aberman; Michael L Hawes; Kaspar M Keledjian; Luke S Jones; Eduardo D Rodriguez
Journal:  Ann Plast Surg       Date:  2011-04       Impact factor: 1.539

5.  The use of acellular dermal matrix to prevent capsule formation around implants in a primate model.

Authors:  Amy Stump; Luther H Holton; Jerome Connor; John R Harper; Sheri Slezak; Ronald P Silverman
Journal:  Plast Reconstr Surg       Date:  2009-07       Impact factor: 4.730

6.  Acellular cadaveric dermis decreases the inflammatory response in capsule formation in reconstructive breast surgery.

Authors:  C Bob Basu; Mimi Leong; M John Hicks
Journal:  Plast Reconstr Surg       Date:  2010-12       Impact factor: 4.730

7.  Pelvic, abdominal, and chest wall reconstruction with AlloDerm in patients at increased risk for mesh-related complications.

Authors:  Charles E Butler; Howard N Langstein; Steven J Kronowitz
Journal:  Plast Reconstr Surg       Date:  2005-10       Impact factor: 4.730

8.  Reconstruction of hip stability after proximal and total femur resections.

Authors:  J Bickels; I Meller; R M Henshaw; M M Malawer
Journal:  Clin Orthop Relat Res       Date:  2000-06       Impact factor: 4.176

9.  Use of human acellular dermal matrix in complex and contaminated abdominal wall reconstructions.

Authors:  Joe H Patton; Stepheny Berry; Kurt A Kralovich
Journal:  Am J Surg       Date:  2007-03       Impact factor: 2.565

10.  Reconstruction of complex abdominal wall hernias using acellular human dermal matrix: a single institution experience.

Authors:  Hsinchen Jean Lin; Nicholas Spoerke; Clifford Deveney; Robert Martindale
Journal:  Am J Surg       Date:  2009-05       Impact factor: 2.565

  10 in total
  1 in total

1.  A new method using xenogeneicacellular dermal matrix in the reconstruction of lacrimal drainage.

Authors:  Li Chen; Bo Gong; Zhengzheng Wu; Jacquelyn Jetton; Rong Chen; Chao Qu
Journal:  Br J Ophthalmol       Date:  2014-06-11       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.